U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07635914) titled 'A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension' on May 29.
Brief Summary: Aprocitentan tablets are currently the only endothelin dual receptor antagonist approved internationally for the treatment of resistant hypertension.This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of aprocitentan tablets(SYH9108) in patients with treatment-resistant hypertension (rHTN)
Study Start Date: May 31
Study Type: INTERVENTIONAL
Condition:
Resistant Hypertension
Intervention:
DRUG: Aprocitentan tablets(SYH9108)
For oral administrat...